The U.S. Food and Drug Administration is considering permitting compounding pharmacies to manufacture over a dozen injectable peptides that were previously banned due to significant safety concerns.
In 2023, the FDA removed 14 peptides from the list of products that compounding pharmacies are permitted to produce. These compounded peptides were widely used in wellness, integrative medicine, and sports medicine.
Read Also – US FDA Issues Warning on Liver Injury Linked to Amgen’s Rare Disease Medication
The agency had previously stated that the decision was based on significant safety concerns, including risks related to immunogenicity, toxicity, and impurities in the peptides.
Health Secretary Robert F. Kennedy Jr. has publicly expressed support for peptide use, noting in a recent podcast that he is a “big fan of peptides” and has personally experienced “really good effects” from them.
Peptides are short chains of amino acids, essentially fragments of larger proteins, and they occur naturally in the human body.
One of the most well-known peptides is insulin, a 51-amino-acid hormone that regulates blood sugar. Insulin was also the first peptide to be synthesized outside the body and developed into a medical treatment.
